WTA
TAK icon

Washington Trust Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Washington Trust Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35
Closed -$1K – 989
2022
Q1 		$1K Hold
35
– – ﹤0.01% 983
2021
Q4 		$0 Buy
+35
New +$491 ﹤0.01% 1001

Other funds holding TAK

MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Washington Trust Advisors's TAK Position: Q2 2022 in Review

Washington Trust Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 35 shares — an estimated $1K sold.

Washington Trust Advisors first reported a position in TAK in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 282 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

  • Washington Trust Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 35 Takeda Pharmaceutical shares in Q2 2022, an estimated $1K.
  • Washington Trust Advisors first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 2 quarters.
  • Washington Trust Advisors's Takeda Pharmaceutical position peaked at $1K in Q1 2022.
  • 282 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Washington Trust Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.